Total
0
Shares
President, André Larente
Source: La Presse

Subscribe

Be the first with the news that moves the market
  • Medical technology company, DIAGNOS (ADK) has revealed a new service agreement with the Colombian Telemedicine Centre (CTMC)
  • The CTMC will use the company’s AI engine CARA to begin screening Colombia’s population for eye-related issues
  • CARA (Computer Assisted Retina Analysis) integrates with existing equipment, and makes standard retinal images sharper, clearer, and easier to read
  • The two parties plan to begin the screening project in two major regions of Colombia in the following weeks
  • Before the market opens, DIAGNOS (ADK) is trading at C$0.17 per share 

Medical technology company, DIAGNOS (ADK) has revealed a new service agreement with the Colombian Telemedicine Centre (CTMC).

The CTMC has chosen DIAGNOS and its artificial intelligence engine, CARA, for a screening project. In alliance with the country's largest specialist centre, the CTMC will use CARA to screen Colombia’s population for eye-related issues.

The CTMC’s founder, Dr Jorge Alberto Velez B, said this will unburden the heavy costs of blindness caused by diabetes.

CARA (Computer Assisted Retina Analysis) is a tele-ophthalmology platform that integrates with pre-existing hardware or software. The tool’s image enhancement algorithms make standard images of a person’s retina sharper, clearer, and easier to read. 

CARA can process results at the point of care, which will empower local technicians. However, specialists will validate the automated results before scheduling follow-ups with patients requiring further treatment.  

The CTMC and DIAGNOS plan to start the screening project in two major regions of Colombia, in the coming weeks.

DIAGNOS’ President, André Larente, commented on the service agreement with Colombia’s Telemedicine Centre. 

“We would like to thank the CTMC for choosing our CARA platform. We believe that CARA is a perfect fit as the main engine of the telemedicine solution.

“After a successful eye screening program with Bayer in 2015, we return to Colombia to engage our AI service into a practical solution for the local community. Along with CTMC, we can add value by making our unique service accessible,” he said. 

Before the market opens, DIAGNOS (ADK) is trading at C$0.17 per share.

More From The Market Herald

" Wellteq (CSE:WTEQ) collaborates with Garmin to counter COVID-19

Wellteq (WTEQ) is collaborating with Garmin to offer new enterprise wellness solutions in the Asia Pacific region in response to recent COVID-19 surges.

" ScreenPro (CSE:SCRN) completed over 19,000 COVID-19 tests in May

ScreenPro (SCRN) completed over 19,000 tests for production companies in Toronto and Vancouver in May.

" Medicenna (TSX:MDNA) submits clinical trial application for a Phase 1/2 study of MDNA11

Medicenna Therapeutics Corp. (MDNA) has submitted a clinical trial application to initiate a Phase 1/2 clinical study of MDNA11

" Entheon Biomedical (CSE:ENBI) subsidiary partners with 3W Wellness

Entheon Biomedical (ENBI) subsidiary, HaluGen Life Sciences, has partnered with 3W Wellness to drive brand awareness.